Sergey Shcherbinin1, Orla Doyle2, Fernando O Zelaya2, Sara de Simoni2, Mitul A Mehta2, Adam J Schwarz3. 1. Tailored Therapeutics - Neuroscience, Eli Lilly and Company, Indianapolis, IN, 46285, USA. 2. Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. 3. Tailored Therapeutics - Neuroscience, Eli Lilly and Company, Indianapolis, IN, 46285, USA. a.schwarz@lilly.com.
Abstract
RATIONALE: Resting brain perfusion, measured using the MRI-based arterial spin labelling (ASL) technique, is sensitive to detect central effects of single, clinically effective, doses of pharmacological compounds. However, pharmacological interaction experiments, such as the modulation of one drug response in the presence of another, have not been widely investigated using a task-free ASL approach. OBJECTIVES: We assessed the effects of three psychoactive compounds (ketamine, risperidone and lamotrigine), and their interaction, on resting brain perfusion in healthy human volunteers. METHODS: A multivariate Gaussian process classification (GPC) and more conventional univariate analyses were applied. The four pre-infusion conditions for each subject comprised risperidone, lamotrigine and two placebo sessions. The two placebo conditions enabled us to evaluate the classification performance in a test-retest setting, in addition to its performance in distinguishing the active oral drugs from placebo (direct effect on brain perfusion). The post ketamine- or saline-infusion scans allowed the effect of ketamine, and its interaction with risperidone and lamotrigine, on brain perfusion to be characterised. RESULTS: The pseudo-continuous ASL measurements of perfusion were sensitive to the effects of ketamine infusion and risperidone. The GPC captured consistent changes in perfusion across the group and contextualised the univariate changes with a larger pattern of regions contributing to accurate discrimination of ketamine from placebo. CONCLUSIONS: The findings argue against perfusion changes confounding in the previously described evoked BOLD response to ketamine and emphasise the blockade of the NMDA receptor over neuronal glutamate release in determining the perfusion changes induced by ketamine.
RCT Entities:
RATIONALE: Resting brain perfusion, measured using the MRI-based arterial spin labelling (ASL) technique, is sensitive to detect central effects of single, clinically effective, doses of pharmacological compounds. However, pharmacological interaction experiments, such as the modulation of one drug response in the presence of another, have not been widely investigated using a task-free ASL approach. OBJECTIVES: We assessed the effects of three psychoactive compounds (ketamine, risperidone and lamotrigine), and their interaction, on resting brain perfusion in healthy human volunteers. METHODS: A multivariate Gaussian process classification (GPC) and more conventional univariate analyses were applied. The four pre-infusion conditions for each subject comprised risperidone, lamotrigine and two placebo sessions. The two placebo conditions enabled us to evaluate the classification performance in a test-retest setting, in addition to its performance in distinguishing the active oral drugs from placebo (direct effect on brain perfusion). The post ketamine- or saline-infusion scans allowed the effect of ketamine, and its interaction with risperidone and lamotrigine, on brain perfusion to be characterised. RESULTS: The pseudo-continuous ASL measurements of perfusion were sensitive to the effects of ketamine infusion and risperidone. The GPC captured consistent changes in perfusion across the group and contextualised the univariate changes with a larger pattern of regions contributing to accurate discrimination of ketamine from placebo. CONCLUSIONS: The findings argue against perfusion changes confounding in the previously described evoked BOLD response to ketamine and emphasise the blockade of the NMDA receptor over neuronal glutamate release in determining the perfusion changes induced by ketamine.
Authors: Johannes Tauscher; Shitij Kapur; N Paul L G Verhoeff; Douglas F Hussey; Zafiris J Daskalakis; Sitra Tauscher-Wisniewski; Alan A Wilson; Sylvain Houle; Siegfried Kasper; Robert B Zipursky Journal: Arch Gen Psychiatry Date: 2002-06
Authors: Andre Marquand; Matthew Howard; Michael Brammer; Carlton Chu; Steven Coen; Janaina Mourão-Miranda Journal: Neuroimage Date: 2009-10-29 Impact factor: 6.556
Authors: Najmeh Khalili-Mahani; Marieke Niesters; Matthias J van Osch; Melly Oitzl; Ilya Veer; Mark de Rooij; Joop van Gerven; Mark A van Buchem; Christian F Beckmann; Serge A R B Rombouts; Albert Dahan Journal: Neuroimage Date: 2014-12-29 Impact factor: 6.556
Authors: O M Doyle; S De Simoni; A J Schwarz; C Brittain; O G O'Daly; S C R Williams; M A Mehta Journal: J Pharmacol Exp Ther Date: 2013-01-31 Impact factor: 4.030
Authors: S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta Journal: Neuroimage Date: 2012-09-23 Impact factor: 6.556
Authors: Anna Höflich; Andreas Hahn; Martin Küblböck; Georg S Kranz; Thomas Vanicek; Christian Windischberger; Alois Saria; Siegfried Kasper; Dietmar Winkler; Rupert Lanzenberger Journal: Int J Neuropsychopharmacol Date: 2015-04-19 Impact factor: 5.176
Authors: Fernanda Palhano-Fontes; Katia C Andrade; Luis F Tofoli; Antonio C Santos; Jose Alexandre S Crippa; Jaime E C Hallak; Sidarta Ribeiro; Draulio B de Araujo Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: Duncan J Hodkinson; Owen O'Daly; Patricia A Zunszain; Carmine M Pariante; Vitaly Lazurenko; Fernando O Zelaya; Matthew A Howard; Steven C R Williams Journal: J Cereb Blood Flow Metab Date: 2014-06-18 Impact factor: 6.200
Authors: Jennifer H Foss-Feig; Brendan D Adkinson; Jie Lisa Ji; Genevieve Yang; Vinod H Srihari; James C McPartland; John H Krystal; John D Murray; Alan Anticevic Journal: Biol Psychiatry Date: 2017-03-14 Impact factor: 13.382
Authors: Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach Journal: Harv Rev Psychiatry Date: 2018 Nov/Dec Impact factor: 3.732
Authors: Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins Journal: Drug Discov Today Date: 2017-11-15 Impact factor: 7.851
Authors: Jennifer W Evans; Joanna Szczepanik; Nancy Brutsché; Lawrence T Park; Allison C Nugent; Carlos A Zarate Journal: Biol Psychiatry Date: 2018-02-15 Impact factor: 13.382
Authors: Peter C T Hawkins; Tobias C Wood; Anthony C Vernon; Alessandro Bertolino; Fabio Sambataro; Juergen Dukart; Emilio Merlo-Pich; Celine Risterucci; Hanna Silber-Baumann; Eamonn Walsh; Ndabezinhle Mazibuko; Fernando O Zelaya; Mitul A Mehta Journal: Hum Brain Mapp Date: 2017-10-23 Impact factor: 5.038
Authors: Deborah A Yurgelun-Todd; Perry F Renshaw; Paul Goldsmith; Tolga Uz; Thomas A Macek Journal: Psychopharmacology (Berl) Date: 2019-11-26 Impact factor: 4.530
Authors: Nick Medford; Mauricio Sierra; Argyris Stringaris; Vincent Giampietro; Michael J Brammer; Anthony S David Journal: Front Psychol Date: 2016-06-02
Authors: Grant McQueen; John Lally; Tracy Collier; Fernando Zelaya; David J Lythgoe; Gareth J Barker; James M Stone; Philip McGuire; James H MacCabe; Alice Egerton Journal: Psychopharmacology (Berl) Date: 2018-08-23 Impact factor: 4.530